Hepatocellular carcinoma (HCC) can develop without obvious symptoms. For people at increased risk, waiting until symptoms appear may mean losing valuable opportunities for timely evaluation.
Regular surveillance is intended to identify suspicious changes as early as possible. Its purpose is not to rely on one test, but to bring together risk assessment, imaging, laboratory findings and appropriate clinical follow-up.
Liver Cancer Can Develop Silently
Early HCC may produce few or no symptoms. Feeling well therefore does not reliably exclude disease in a person with an elevated underlying risk.
For eligible high-risk individuals, ongoing surveillance is more useful than waiting for pain, weight loss, fatigue, jaundice or other symptoms to prompt medical attention.
Who Is at Increased Risk?
HCC frequently arises in people with chronic liver disease. Important risk factors include cirrhosis, chronic hepatitis B and some patients with chronic hepatitis C, particularly when advanced liver fibrosis or cirrhosis is present.
Not everyone with these conditions requires the same surveillance strategy. Eligibility depends on the condition, age, other risk factors and whether detecting HCC could lead to beneficial care.
Why Earlier Detection Matters
The stage at which HCC is identified can affect treatment choices. Localized disease may make a patient eligible for potentially curative treatments, such as resection, ablation or transplantation when clinically appropriate. More extensive disease may limit these options.
Early detection does not guarantee a cure, but it offers an opportunity to evaluate disease while more choices may remain available.
Current Surveillance Has Limitations
Liver ultrasound is a commonly recommended surveillance method, often used with alpha-fetoprotein (AFP). However, ultrasound performance varies across patients, and some people with HCC have normal AFP levels.
These limitations motivate research into complementary methods that measure biological information different from conventional imaging or protein biomarkers.
Looking for Molecular Signals in Blood
One area of research involves fusion transcripts—RNA products associated with genomic rearrangements that join portions of two genes. Selected cancer-associated fusion transcripts can be detected as circulating cell-free RNA in serum from people with HCC, according to published studies.
The MoleculeDx Liver Cancer Fusion Predictor, based on Fusion-detect™ technology, examines multiple fusion-transcript signals using a multi-marker approach. Such molecular information must be interpreted alongside appropriate clinical assessment and imaging, not as a replacement for them.
Screening Is About Finding Cancer Before Symptoms
The value of surveillance lies in continuity and timely evaluation. Patients at increased risk should discuss an appropriate surveillance plan with a qualified healthcare professional rather than wait for symptoms.
Earlier evaluation can create more opportunities to make informed decisions.